Trading of Enlivex Therapeutics was halted at 07:40 AM EST due to "News pending". Enlivex Therapeutics (ENLV) Competitors $1.25 -0.57 (-31.32%) Closing price 04:00 PM EasternExtended Trading$1.31 +0.06 (+4.48%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENLV vs. GNLX, CGEN, KRRO, SPRO, BHST, FATE, MCRB, IMRX, PLX, and IKTShould you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Genelux (GNLX), Compugen (CGEN), Korro Bio (KRRO), Spero Therapeutics (SPRO), BioHarvest Sciences (BHST), Fate Therapeutics (FATE), Seres Therapeutics (MCRB), Immuneering (IMRX), Protalix BioTherapeutics (PLX), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Enlivex Therapeutics vs. Its Competitors Genelux Compugen Korro Bio Spero Therapeutics BioHarvest Sciences Fate Therapeutics Seres Therapeutics Immuneering Protalix BioTherapeutics Inhibikase Therapeutics Genelux (NASDAQ:GNLX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Which has better valuation & earnings, GNLX or ENLV? Enlivex Therapeutics has lower revenue, but higher earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K13,370.58-$29.87M-$0.86-4.12Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.89 Do institutionals & insiders believe in GNLX or ENLV? 37.3% of Genelux shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 8.8% of Genelux shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, GNLX or ENLV? Genelux has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Does the media favor GNLX or ENLV? In the previous week, Enlivex Therapeutics had 3 more articles in the media than Genelux. MarketBeat recorded 9 mentions for Enlivex Therapeutics and 6 mentions for Genelux. Enlivex Therapeutics' average media sentiment score of 0.44 beat Genelux's score of -0.02 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is GNLX or ENLV more profitable? Enlivex Therapeutics' return on equity of -57.67% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -107.47% -83.14% Enlivex Therapeutics N/A -57.67%-50.52% Do analysts rate GNLX or ENLV? Genelux presently has a consensus target price of $17.75, suggesting a potential upside of 401.41%. Enlivex Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 700.00%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryEnlivex Therapeutics beats Genelux on 11 of the 14 factors compared between the two stocks. Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENLV vs. The Competition Export to ExcelMetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.56M$2.48B$5.70B$9.79BDividend YieldN/A1.68%3.77%4.10%P/E Ratio-1.8921.6430.8625.25Price / SalesN/A545.59403.9088.50Price / CashN/A25.4525.2228.45Price / Book1.255.559.516.00Net Income-$15.01M$31.83M$3.26B$265.34M7 Day Performance-14.97%4.99%4.49%2.81%1 Month Performance5.04%4.04%5.18%1.50%1 Year Performance-0.86%11.07%31.98%25.46% Enlivex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENLVEnlivex Therapeutics3.3757 of 5 stars$1.25-31.3%$10.00+700.0%+44.4%$29.56MN/A-1.8970News CoverageAnalyst ForecastShort Interest ↓Gap DownTrading HaltedHigh Trading VolumeGNLXGenelux1.5199 of 5 stars$3.51flat$17.75+405.7%+76.2%$132.54MN/A-3.9910News CoveragePositive NewsAnalyst RevisionCGENCompugen2.0182 of 5 stars$1.46-1.4%$4.00+174.0%-22.3%$132.07M$27.86M-9.1370KRROKorro Bio1.4492 of 5 stars$15.49+11.8%$102.43+561.3%-53.9%$130.06M$2.27M-1.6470News CoverageEarnings ReportAnalyst RevisionGap DownSPROSpero Therapeutics3.9362 of 5 stars$2.26-1.7%$5.00+121.2%+60.5%$128.59M$47.98M-1.77150Earnings ReportBHSTBioHarvest SciencesN/A$7.67-0.3%$13.67+78.2%N/A$126.28M$27.70M-15.34N/AEarnings ReportAnalyst RevisionGap UpFATEFate Therapeutics4.0596 of 5 stars$1.06-0.9%$3.83+261.6%-67.9%$122.63M$13.63M-0.71550Earnings ReportAnalyst UpgradeAnalyst RevisionMCRBSeres Therapeutics3.286 of 5 stars$14.78+5.6%$73.67+398.4%-5.1%$122.17M$126.32M-3.21330IMRXImmuneering3.578 of 5 stars$3.43+1.8%$13.25+286.3%+265.0%$121.27MN/A-1.7560Earnings ReportUpcoming EarningsPLXProtalix BioTherapeutics3.2227 of 5 stars$1.50+3.4%$15.00+900.0%+52.4%$119.41M$59.76M-11.54200Gap UpIKTInhibikase Therapeutics2.0326 of 5 stars$1.60+5.3%$6.50+306.3%+37.8%$118.95MN/A-0.606 Related Companies and Tools Related Companies GNLX Competitors CGEN Competitors KRRO Competitors SPRO Competitors BHST Competitors FATE Competitors MCRB Competitors IMRX Competitors PLX Competitors IKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENLV) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access